PLRZ — Polyrizon Ltd.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1893645 ·
Israel
Last close
$11.25
Market Cap
$21.06M
52W High
$17.95
52W Low
$10.31
ADV30
49,993
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 21,437,000 | 1,306,000 | 443,000 |
| Jun 2025 | — | — | — | — | 18,739,000 | 15,828,000 | 364,000 |
| Dec 2024 | — | — | — | — | 5,547,000 | 2,554,000 | 261,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-8,401,000
Inventory
—
Receivables
—
ST Investments
$11,158,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,785,000 | -3,335,000 | 21,437,000 | 443,000 | — | -4,528,000 |
| Dec 2024 | 0 | -1,302,000 | -1,545,000 | 5,547,000 | 261,000 | — | -1,147,000 |
| Dec 2023 | 0 | -635,000 | -600,000 | 559,000 | 750,000 | — | -537,000 |
| Dec 2022 | 0 | -895,000 | -779,000 | 546,000 | 1,446,000 | — | -1,132,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFWD | Lifeward Ltd. | $20.32M | $7.22 | — |
| RVP | RETRACTABLE TECHNOLOGIES INC | $19.76M | $0.66 | — |
| CTSO | Cytosorbents Corp | $22.69M | $0.36 | — |
| PLSM | Pulsenmore Ltd. | $23.74M | $3.65 | — |
| HRGN | Harvard Apparatus Regenerative Technology, Inc. | $18.28M | $1.04 | — |
News headlines (Yahoo Finance, 1h cache)
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ)
2026-07-02 12:29 · Yahoo
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
2026-07-02 11:32 · Yahoo
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial
2026-06-29 12:44 · Yahoo
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
2026-06-17 12:15 · Yahoo
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
2026-06-15 12:05 · Yahoo
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
2026-06-10 11:47 · Yahoo
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
2026-06-08 13:25 · Yahoo
Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
2026-05-13 13:25 · Yahoo
Polyrizon Announces U.S. Patent Expansion for Its Intranasal Drug Delivery Platform
2026-05-04 12:45 · Yahoo
Polyrizon Announces Filing of European Patent Application for Its Breakthrough Drug Delivery Platform
2026-04-27 13:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.